autoimmune disorders

Tirabrutinib hydrochloride is a potent, highly selective, and irreversible oral BTK inhibitor. Tirabrutinib hydrochloride irreversibly covalently binds to Bruton tyrosine kinase (BTK) in B cells and exhibits potent in vitro cytotoxicity against many types of B cell malignancies, as well as in vivo antitumor activity in mouse models [1].

Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.

JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) intended for the treatment of organ transplantation rejection, graft-versus-host reaction post-transplantation, autoimmune disorders, allergic diseases, and chronic myeloproliferative disorders.

(R)-Lisofylline ((R)-Lisophylline) is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 µM) that interrupts IL-12 signaling-mediated STAT4 activation, making it useful for studies on the treatment of type 1 diabetes and autoimmune disorders.

β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases.

MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.13460-73-86-5

Feeblin(IRF5-IN-1) is a protein degradation inducer that specifically blocks pro-inflammatory signaling pathways associated with autoimmune diseases and can be used to study immune system disorders in the class of systemic lupus erythematosus.

OGT inhibitor 4a is an O-linked n-acetylglucosaminyltransferase (OGT) inhibitor with anticancer activity for the study of autoimmune and neurological disorders.

HPN-01 (IKK inhibitor XII) is a selective IKK inhibitor that inhibits IKK-α, IKK-β, and IKK-ε. HPN-01 reduces the severity of the disease, attenuates the immune imbalance, and prolongs the lifespan of mice in a model of autoimmune encephalomyelitis, and can be used to study immune disorders.

Zaurategrast ethyl ester sulfate is a α4β1/α4β7 integrin antagonist, and used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester is the ethyl ester prodrug of CT7758 and is an α4β1/α4β7 integrin antagonist. It is used for the treatment of inflammatory and autoimmune disorders.

GRK6-IN-4 is an inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 value of 1.56 μM. GRK6-IN-4 is applicable for research related to hematological malignancies, inflammatory diseases, and autoimmune disorders.

Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.

MK2-IN-7 (Compound 144) is an inhibitor of mitogen-activated protein kinase-activated protein kinase-2 (MK2). It shows potential for research in inflammatory diseases, autoimmune disorders, and cancer.

GRK6-IN-5 is an inhibitor of the GRK6 polypeptide, with an IC50 of 4.48 μM. GRK6-IN-5 is utilized in research focused on hematological malignancies, inflammatory diseases, and autoimmune disorders.

RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (Receptor Interacting Protein Kinase 1) with an IC50 value of 16 nM. It holds potential for research in areas such as infections, autoimmune disorders, and neurodegenerative diseases.

PAD-IN-3 (Compound 16) is a potent dual inhibitor of peptidylarginine deiminase 4 (PAD4) and PAD1, with IC50 values of 0.204 μM and 0.273 μM, respectively. It has potential applications in the research of citrullination-related diseases such as cancer and autoimmune disorders.

PAD2/4-IN-1 is an orally active inhibitor of PAD2 and PAD4, with IC50 values of 23 and 10 nM, respectively. It inhibits protein citrullination in neutrophils and reduces hERG channel toxicity. PAD2/4-IN-1 is applicable in research on autoimmune diseases, neurological disorders, and cancer.

MRT-7612 (Compound 4) is a cereblon-based molecular glue degrader targeting tyrosine kinases. It significantly induces the degradation of HCK and LYN, with a comparatively weaker effect on LCK. MRT-7612 is applicable in research related to cancers such as chronic myeloid leukemia, autoimmune disorders, and chronic inflammatory diseases.

ND-2110, a selective interleukin-1 receptor-associated kinase 4 inhibitors, is used for the treatment of autoimmune disorders and lymphoid malignancy.

CTA 056 is an interleukin-2 induced T cell kinase (ITK) inhibitor, inhibits the growth of MOLT-4 xenograft tumors in mice, induces apoptosis in Jurkat cells, and can be used in the study of autoimmune disorders and T cell malignancies.

LYP-IN-1 is a potent and highly selective inhibitor of lymphoid-specific tyrosine phosphatase (LYP), with a Ki value of 110 nM and an IC50 of 0.259 μM. LYP-IN-1 exhibits additional selectivity against a broad range of PTPs, including SHP1 (IC50 = 5 μM) and SHP2 (IC50 = 2.5 μM). LYP-IN-1 demonstrates strong efficacy in both T cells and mast cells, making it a valuable compound for research into autoimmune disorders and immune signaling pathways.

Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.

Zectivimod, a sphingosine-1-phosphate receptor agonist, holds the potential for studying autoimmune diseases, chronic inflammatory diseases, and immunoregulation disorders.